Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT04932148
Recruiting Not applicable

INCremental Dialysis to Improve Health Outcomes in People Starting Haemodialysis (INCH-HD)

NCT04932148 · tracked via the Priya Life Science Australia tracker
Sponsor
The University of Queensland
Phase
Not applicable
Started
2022-07-06
Last updated
2026-05-13

Condition(s) studied

Kidney Failure

Investigational drug(s) / intervention(s)

Incremental HDConventional HD

Incremental HD: Starting haemodialysis at twice weekly frequency

Conventional HD: Starting haemodialysis at thrice weekly frequency

Study summary

The INCH-HD trial will test if incremental HD preserves the quality of life of patients and families and is a safe, practical, cost effective treatment option.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adults (≥ 18 years of age) and 2. Commencing HD as their initial dialysis therapy and 3. Able to give informed consent Exclusion Criteria: 1. Urine output \<0.5Litres/day 2. Unlikely to be on HD for ≥1 year.

Primary outcome measure(s)

  • Heath related quality of life — 6 months
    This will be measured using Kidney-specific component (KSC) of the Kidney Disease Quality of Life Short Form (KDQOL-SF) V1.3 questionnaire. The KSC is the mean of the 11 domains of the kidney-disease specific items of KDQOL-SF. Scores are transformed onto a 0-100 range, where a higher score reflects a better quality of life.

Trial sites (18)

FacilityCityRegionStatus
Concord Repatriation General Hospital Concord New South Wales Recruiting
Northern Beaches Hospital Frenchs Forest New South Wales Not Yet Recruiting
St George Hospital Kogarah New South Wales Recruiting
Liverpool Hospital Liverpool New South Wales Recruiting
John Hunter Hospital New Lambton Heights New South Wales Recruiting
Port Macquarie Hospital Port Macquarie New South Wales Recruiting
Royal North Shore Hospital Saint Leonards New South Wales Not Yet Recruiting
Bundaberg Hospital Bundaberg Queensland Recruiting
Cairns Hospital Cairns Queensland Recruiting
Redland Hospital Cleveland Queensland Not Yet Recruiting
Logan Hospital Logan City Queensland Recruiting
Toowoomba Hospital Toowoomba Queensland Recruiting
Princess Alexandra Hospital Woolloongabba Queensland Recruiting
Royal Adelaide Hospital Adelaide South Australia Recruiting
Monash Health Melbourne Victoria Recruiting
Eastern Health Melbourne Victoria Recruiting
Fiona Stanley Hospital Murdoch Washington Not Yet Recruiting
University Health Network- University of Toronto Toronto Ontario Not Yet Recruiting

More The University of Queensland trials in Australia

Pasteurised Donor Human Milk Supplementation for Term Babies Recruiting
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) Recruiting
Load Incorporating Cardiac Assessment by Echocardiography In Patients With SEpsis (LIAISE Study) Starting soon
STarting incrEmental Prescription of Peritoneal Dialysis Recruiting
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial Recruiting

Other trials for the same condition

STarting incrEmental Prescription of Peritoneal Dialysis Recruiting
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04932148 on ClinicalTrials.gov ↗ ← All trials in Australia